{"id":5282,"date":"2010-12-08T06:13:49","date_gmt":"2010-12-08T11:13:49","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=5282"},"modified":"2011-07-19T17:44:41","modified_gmt":"2011-07-19T21:44:41","slug":"third-times-the-charm-fda-panel-finally-backs-an-obesity-pill","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/12\/08\/third-times-the-charm-fda-panel-finally-backs-an-obesity-pill\/","title":{"rendered":"Third Time&#8217;s the Charm: FDA Panel Finally Backs an Obesity Pill"},"content":{"rendered":"<p>Following rejections earlier this year of two previous anti-obesity drugs, the FDA\u2019s Endocrinologic and Metabolic Drugs advisory committee <a href=\"http:\/\/ir.orexigen.com\/phoenix.zhtml?c=207034&amp;p=irol-newsArticle&amp;ID=1505602&amp;highlight=\">has recommended approval for Contrave<\/a>, the combination of sustained-release formulations of naltrexone and buproprion from Orexigen Therapeutics.<\/p>\n<p>The committee voted 13-7 in favor of the drug, saying that the benefits of Contrave outweighed its risks. The committee also voted 11-8 that the company should conduct a large safety trial following approval of the drug. The same panel voted against recommending approval for lorcaserin (Arena) and Qnexa (Vivus) earlier this year.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Following rejections earlier this year of two previous anti-obesity drugs, the FDA\u2019s Endocrinologic and Metabolic Drugs advisory committee has recommended approval for Contrave, the combination of sustained-release formulations of naltrexone and buproprion from Orexigen Therapeutics. The committee voted 13-7 in favor of the drug, saying that the benefits of Contrave outweighed its risks. The committee [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,7],"tags":[603,602,222],"class_list":["post-5282","post","type-post","status-publish","format-standard","hentry","category-general","category-prevention","tag-antiobesity-pills","tag-contrave","tag-fda-approvals"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/5282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=5282"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/5282\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=5282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=5282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=5282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}